The Cardiac Late Sodium Channel Current is a Molecular Target for the Sodium-Glucose Co-Transporter 2 Inhibitor Empagliflozin
Sodium/glucose co-transporter 2 SGLT2 inhibitors exert cardioprotective effects against heart failure in diabetes patients. There is intense interest to identify the underlying molecular mechanisms that afford this protection. SGLT2 inhibitors reduced late-INa in cardiomyocytes from mice with heart failure. In an acute model of myocardial injury, perfusion of isolated mouse hearts with empagliflozin prevented activation of the cardiac NLRP3 inflammasome.
